Women's Health
From the Journals
HT, even short-term use, linked to dementia risk in women
Short-term and cyclical use of estrogen and progestin therapy for menopausal symptoms is linked to an increased risk of dementia.
Practice Alert
Should breast cancer screening start at a younger age?
This month, Dr. Campos-Outcalt discusses the rationale for and implications of the USPSTF’s draft recommendations on breast cancer screening,...
Latest News
HPV rates skyrocket despite safe, effective vaccine
Low public awareness of the dangers of HPV may be behind young people’s poor vaccination rates.
From the Journals
Vaginal microbiota transfer may affect neurodevelopment in cesarean infants
The value of vaginal microbiota to improve infant outcomes remains uncertain, but safety data are strong.
Latest News
Malpractice lawsuits over denied abortion care may be on the horizon
A hurdle for malpractice cases is that state abortion bans could undermine the argument that abortion is the legal “standard of care.”
From the Journals
Breast cancer family history linked to better BC survival
A family history of breast cancer was associated with a lower risk of breast cancer-specific death, after adjustments, a new study finds.
Commentary
Does ‘skeletal age’ describe fracture impact on mortality?
Mortality risk may be related to patients not fully understanding the consequence of a fragility fracture.
Conference Coverage
Migraine device expands treatment possibilities
New studies of remote electrical neuromodulation show efficacy in adolescents and safety during pregnancy.
From the Journals
Combo treatment eases nausea and vomiting of pregnancy
Some women have such severe nausea they are literally starving and so weak they are bedridden or even hospitalized.
Conference Coverage
A ‘one-stop shop’: New guidance on hormones and aging
Part of what we need to do is [provide] the evidence that we have, which includes evidence of when not to prescribe as well as [when] to prescribe...
Commentary
A new nonhormonal option for menopausal hot flashes: What prescribers should know
In two phase 3 clinical trials, fezolinetant 45 mg reduced the frequency of vasomotor symptoms by about 65%.